These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27408930)

  • 1. Deep morphea induced by interferon-β1b injection.
    Lee EY; Glassman SJ
    JAAD Case Rep; 2016 May; 2(3):236-8. PubMed ID: 27408930
    [No Abstract]   [Full Text] [Related]  

  • 2. Morphea secondary to interferon beta1b injection: a case and review of the literature.
    Ozlu E; Karadag AS; Akdeniz N; Uzuncakmak TK; Zemheri E; Ozkanli S
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
    Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of interferon-β1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
    Wostradowski T; Gudi V; Pul R; Gingele S; Lindquist JA; Stangel M; Lindquist S
    Clin Exp Immunol; 2015 Nov; 182(2):162-72. PubMed ID: 26212126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-beta1b for the treatment of multiple sclerosis.
    Lam S; Wang S; Gottesman M
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
    Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis.
    Monzani F; Caraccio N; Meucci G; Lombardo F; Moscato G; Casolaro A; Ferdeghini M; Murri L; Ferrannini E
    Eur J Endocrinol; 1999 Oct; 141(4):325-31. PubMed ID: 10526243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta-1a-induced morphea.
    Bezalel SA; Strober BE; Ferenczi K
    JAAD Case Rep; 2015 Jan; 1(1):15-7. PubMed ID: 27075128
    [No Abstract]   [Full Text] [Related]  

  • 10. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
    Alexander JS; Harris MK; Wells SR; Mills G; Chalamidas K; Ganta VC; McGee J; Jennings MH; Gonzalez-Toledo E; Minagar A
    Mult Scler; 2010 Jul; 16(7):801-9. PubMed ID: 20621951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No evidence for increased frequency of autoantibodies during interferon-beta1b treatment of multiple sclerosis.
    Kivisäkk P; Lundahl J; von Heigl Z; Fredrikson S
    Acta Neurol Scand; 1998 May; 97(5):320-3. PubMed ID: 9613562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
    Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
    J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity.
    Zvonova EA; Ershov AV; Ershova OA; Sudomoina MA; Degterev MB; Poroshin GN; Eremeev AV; Karpov AP; Vishnevsky AY; Goldenkova-Pavlova IV; Petrov AV; Ruchko SV; Shuster AM
    Appl Microbiol Biotechnol; 2017 Mar; 101(5):1975-1987. PubMed ID: 27833991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-beta1b for multiple sclerosis.
    Burks J
    Expert Rev Neurother; 2005 Mar; 5(2):153-64. PubMed ID: 15853486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
    Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
    Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
    Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
    Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial analysis of soluble intercellular adhesion molecule-1 level in relapsing-remitting multiple sclerosis patients during IFN-beta1b treatment.
    Kilinc M; Saatci-Cekirge I; Karabudak R
    J Interferon Cytokine Res; 2003 Mar; 23(3):127-33. PubMed ID: 12716484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis.
    Kraus J; Bauer R; Chatzimanolis N; Engelhardt B; Tofighi J; Bregenzer T; Kuehne BS; Stolz E; Blaes F; Morgen K; Traupe H; Kaps M; Oschmann P
    J Neurol; 2004 Apr; 251(4):464-72. PubMed ID: 15083294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.
    Freeman JA; Thompson AJ; Fitzpatrick R; Hutchinson M; Miltenburger C; Beckmann K; Dahlke F; Kappos L; Polman C; Pozzilli C;
    Neurology; 2001 Nov; 57(10):1870-5. PubMed ID: 11723278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis.
    Matusevicius D; Kivisakk P; Navikas V; Tian W; Soderstrom M; Fredrikson S; Link H
    Eur J Neurol; 1998 May; 5(3):265-275. PubMed ID: 10210841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.